Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sophie Hans"'
Autor:
Fathia Mami-Chouaib, Charlotte Blanc, Stéphanie Corgnac, Sophie Hans, Ines Malenica, Clémence Granier, Isabelle Tihy, Eric Tartour
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract CD8+ T lymphocytes are the major anti-tumor effector cells. Most cancer immunotherapeutic approaches seek to amplify cytotoxic T lymphocytes (CTL) specific to malignant cells. A recently identified subpopulation of memory CD8+ T cells, named
Externí odkaz:
https://doaj.org/article/d98e668c65724982ad3748a51666d9b1
Autor:
Charlotte Blanc, Sophie Hans, Thi Tran, Clemence Granier, Antonin Saldman, Marie Anson, Stephane Oudard, Eric Tartour
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
A novel population of memory CD8+ T cells called resident memory T cells (TRM) has been identified based on their phenotype (CD103, CD69) and on their local tissue residency without recirculating in the blood. These cells have been implicated in prot
Externí odkaz:
https://doaj.org/article/33b05205db18461da5962fdfe1d15e0f
Autor:
Laurent Dercle, Shawn Sun, Romain-David Seban, Ahmed Mekki, Roger Sun, Lambros Tselikas, Sophie Hans, Alice Bernard-Tessier, Fadila Mihoubi Bouvier, Nicolas Aide, Laetitia Vercellino, Alexia Rivas, Antoine Girard, Fatima-Zohra Mokrane, Guillaume Manson, Roch Houot, Egesta Lopci, Randy Yeh, Samy Ammari, Lawrence H. Schwartz
Publikováno v:
Radiology
Radiology, 2023, 306 (1), pp.32-46. ⟨10.1148/radiol.210518⟩
Radiology, 2023, 306 (1), pp.32-46. ⟨10.1148/radiol.210518⟩
International audience; Criteria based on measurements of lesion diameter at CT have guided treatment with historical therapies due to the strong association between tumor size and survival. Clinical experience with immune checkpoint modulators shows
Autor:
Laurent Dercle, Samy Ammari, Elvire Roblin, Amelie Bigorgne, Stéphane Champiat, Lokmane Taihi, Athèna Plaian, Sophie Hans, Sara Lakiss, Lambros Tselikas, Mathieu Rouanne, Eric Deutsch, Lawrence H. Schwartz, Mithat Gönen, Jessica Flynn, Christophe Massard, Jean-Charles Soria, Caroline Robert, Aurélien Marabelle
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2022, 177, pp.80-93. ⟨10.1016/j.ejca.2022.08.034⟩
European Journal of Cancer, 2022, 177, pp.80-93. ⟨10.1016/j.ejca.2022.08.034⟩
International audience; Aim: Anti-PD-(L)1 immunotherapies improve survival in multiple cancers but remain ineffective for most patients. We applied machine-learning algorithms and multivariate analyses on baseline medical data to estimate their relat
Autor:
Stéphane Champiat, Christophe Massard, Anne-Laure Voisin, Capucine Baldini, Benjamin Besse, Cedric Pobel, Vincent Thomas de Montpréville, Laurence Albiges, Christina Mateus, Jérôme Le Pavec, Samy Ammari, Aurélien Marabelle, Noémie Chanson, Patricia Pautier, Jean-Marie Michot, Patricia Romano-Martin, Charlotte Cabanié, François-Xavier Danlos, Caroline Even, Olivier Lambotte, Sophie Hans, Emilie Routier, A. Laparra, Celine Boutros, Corinne Balleyguier, Romain David Seban, Samuel Dolidon, Caroline Robert
Publikováno v:
European Journal of Cancer. 156:46-59
Sarcoid-like granulomatosis (SLG) reaction caused by immunotherapy remains poorly understood. This study aims to investigate the outcome of patients with cancer and SLG associated with immunotherapy.Between April 2016 and June 2020, 434 patients with
Autor:
Sophie Hans, Yidan Cao, J. Craig Bennett, Mark N. Obrovac, Julia Liese, R. A. Dunlap, Jun Wang, Ulrike Werner-Zwanziger
Publikováno v:
Chemistry of Materials. 33:7386-7395
Autor:
Yann‐Alexandre Vano, Letuan Phan, Gwenaelle Gravis, Iphigénie Korakis, Friederike Schlürmann, Denis Maillet, Mostefa Bennamoun, Nadine Houede, Delphine Topart, Delphine Borchiellini, Philippe Barthelemy, Raffaele Ratta, Thomas Ryckewaert, Ali Hasbini, Sophie Hans, Sheik Emambux, Sandra Cournier, Elena Braychenko, Réza‐Thierry Elaidi, Stéphane Oudard
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩
International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩
International audience; Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib then nivolumab (CN) or nivolumab then cabozantinib (NC), is still unknown. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa55d6650cf0c7bac8f95d4bcfa5b53b
https://amu.hal.science/hal-04084994
https://amu.hal.science/hal-04084994
Autor:
Eric Lechevallier, Dominique Spaeth, Alastair Thomson, Philippe Barthélémy, Jean-Christophe Eymard, Marine Gross-Goupil, Michael Krainer, Amit Bahl, Jean Marc Ferrero, Karim Fizazi, Aude Flechon, Alison Birtle, Sylvestre Le Moulec, Eleni Efstathiou, Jérôme Alexandre, Gedske Daugaard, Constance Thibault, Nicolas Delanoy, Ugo De Giorgi, Tatiana Gavrikova, Ali Hasbini, Brigitte Laguerre, Carole Helissey, Orazio Caffo, Philippe Beuzeboc, Rafael Morales, Anne-Claire Hardy-Bessard, Jean Laurent Deville, Sophie Hans, Simon Chowdhury, Umberto Basso, Frank Priou, Stéphane Oudard, Mohamed Butt, Antoine Thiery-Vuillemin, Avishay Sella, Aline Guillot
Publikováno v:
European Journal of Cancer. 137:290-291
Autor:
Anne-Claire Hardy-Bessard, Jean Laurent Deville, Amit Bahl, Jean-Christophe Eymard, Orazio Caffo, Eleni Efstathiou, Constance Thibault, Sylvestre Le Moulec, Stéphane Oudard, Philippe Beuzeboc, Eric Lechevallier, Ugo De Giorgi, Simon Chowdhury, Dominique Spaeth, Carole Helissey, Philippe Barthélémy, Jérôme Alexandre, Gedske Daugaard, Karim Fizazi, Rafael Morales, Sophie Hans, Alison Birtle, Frank Priou, Avishay Sella, Aline Guillot, Tatiana Gavrikova, Umberto Basso, Nicolas Delanoy, Marine Gross-Goupil, Brigitte Laguerre, Aude Flechon, Ali Hasbini, Mohamed Butt, Antoine Thiery-Vuillemin, Alastair Thomson, Michael Krainer, Jean Marc Ferrero
Publikováno v:
European Journal of Cancer. 137:288-289
Autor:
Juliette Logeart, Yann-Alexandre Vano, Reza Elaidi, Stéphane Oudard, Sophie Hans, A. Simonaggio, Constance Thibault
Publikováno v:
Journal of Clinical Oncology. 38:700-700
700 Background: Nivolumab is an approved standard tretatment for pts with mRCC after one VEGFR-TKI failure. Some reports suggest that Nibolumab provides similar response rate across treatment line. Nevetheless, no comparative data has been reported o